Dynamic needs and challenges of people with drug-resistant tuberculosis and HIV in South Africa: a qualitative study

Abstract

Summary Background There is little evidence of patient acceptability for drug-resistant tuberculosis (DRTB) care in the context of new treatment regimens and HIV co-infection. We aim to describe experiences of DRTB-HIV care among patients in KwaZulu-Natal province, South Africa. Methods In this qualitative study using Bury’s framework for chronic illness, we conducted 13 focus groups at a tertiary hospital with 55 patients co-infected with DRTB and HIV (28 women, 27 men) who were receiving new bedaquiline-based treatment for DRTB, concurrent with antiretroviral therapy. Eligible patients were consenting adults (aged >18 years) with confirmed DRTB and HIV who were enrolled into the PRAXIS study within 2 weeks of initiating bedaquiline-based treatment for DRTB. Participants were recruited from the PRAXIS cohort to participate in a focus group based on their time in DRTB treatment: early (2–6 weeks after treatment initiation), middle (2–6 months after discharge or treatment initiation if never hospitalised), and late (>6 months after treatment initiation). Focus groups were carried out in isiZulu language, audio recorded, and translated to English within 4 weeks. Participants were asked about their experiences of DRTB and HIV care and treatment, and qualitative data were coded and thematically analysed. Findings From March, 2017, to June, 2018, distinctive patient challenges were identified at four critical stages of DRTB care: diagnosis, marked by centralised hospitalisation, renunciation from routine life, systemic stigmatisation and, for patients with longstanding HIV, renewed destabilisation; treatment initiation, marked by side-effects, isolation, and social disconnectedness; discharge, marked by brief respite and resurgent therapeutic and social disruption; and continuity, marked by deepening socioeconomic challenges despite clinical recovery. The periods of diagnosis and discharge into the community were particularly difficult. Treatment information and agency in decision making was a persistent gap. Sources of stigmatisation shifted with movement between the hospital and community. Resilience was built by connecting to peers, self-isolating, financial and material security, and a focus on recovery. Interpretation People with DRTB and HIV undergo disruptive, life-altering experiences. The lack of information, agency, and social protections in DRTB care and treatment causes wider-reaching challenges for patients compared with HIV. Decentralised, community, peer-support, and differentiated care models for DRTB might be ameliorative and help to maximise the promise of new regimens. Funding US National Institutes of Health.

Person‐centred care and short oral treatment for rifampicin‐resistant tuberculosis improve retention in care in Kandahar, Afghanistan

“…With our model of care, we aimed to reduce the period that patients were separated from their family and home and the need for travel in an insecure environment. However, decentralised RR‐TB care would have brought care closer to their homes and would have had fewer social and economic consequences [ 21 , 22 ]. Interventions to mitigate economic loss should be integrated into any RR‐TB control strategy.…”

Epidemiological Characteristics of Infectious Diseases Among Travelers Between China and Foreign Countries Before and During the Early Stage of the COVID-19 Pandemic

“…Our results show that travelers coming from Western Pacific region have the largest number of detected infectious cases, which can be attributed to this region being responsible for the largest number of travelers coming to China. Furthermore, the travelers entering Shanghai Port of China from Africa have the highest detection rate of infectious diseases, which may be attributed to the lack of local health resources and the relatively higher infection rate in Africa ( 31 ). These findings suggest that in the context of international exchanges, the prevention and control of infectious diseases endemic to Africa is an indispensable step in the prevention of global spread of these diseases.…”

Diagnosis and treatment of tuberculosis in adults with HIV

“…[ 29 ] Ten percent of these patients develop resistance mutations to fluoroquinolones and second-line injectable drugs due to improper treatment, which leads to extensively drug-resistant TB (XDR-TB). [ 30 ] DR-TB treatment is more complex, has a higher failure rate, and is more expensive than susceptible TB. The global treatment success rate for MDR/rifampicin-resistant TB in 2020 is 59%.…”